Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated

Fulcrum Therapeutics, Inc.

2025-Q1 EPS reported -$0.28

Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.
Phase 1b PIONEER trial: enrollment complete for 12mg dose cohort (n=16), 20mg cohort started.
On track to report 12mg cohort data in early Q3 2025 and 20mg cohort data by end of 2025.
R&D expenses fell to $13.4M from $19.8M due to losmapimod discontinuation and Sanofi reimbursement.
Cash runway expected to fund operations into at least 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.